Ceri Bygrave

13PUBLICATIONS
36CO-AUTHORS
PharmacogenomicsGene and molecular therapyMedical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 14, 2026
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.

Sosana Delimpasi, Ivan Špička, Jason P Butler

|Oct 17, 2024
Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series.

Nini Aung, Margaret Bowers, Gillian Brearton

|Sep 09, 2024
Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.

Martin Kaiser, Vicky Goh, Simon Stern

|Jul 02, 2024
Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper.

Martin Kaiser, Guy Pratt, Ceri Bygrave

|Jan 03, 2024
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Jahanzaib Khwaja, Joshua Bomsztyk, Maria Atta

|Feb 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.

Annabel McMillan, Supratik Basu, Kamaraj Karunanithi

Pageof 3

Frequent Collaborators

4 joint publications

Guy Pratt

4 joint publications

Martin Kaiser

4 joint publications

Kwee Yong

3 joint publications

Rakesh Popat